1991
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas
Fisher R, Longo D, DeVita V, Hubbard S, Miller T, Young R. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Annals Of Oncology 1991, 2: 33-35. PMID: 1710487, DOI: 10.1093/annonc/2.suppl_1.33.Peer-Reviewed Original ResearchConceptsDisease-free survivalProMACE-MOPPCR rateComplete remissionProMACE-CytaBOMHodgkin's lymphomaLong-term disease-free survivalLong-term disease-free survivorsSurvival curvesStage IIDisease-free survival curvesFirst-generation regimensThird-generation regimensPhase II studyDisease-free survivorsOverall survival curvesSouthwest Oncology GroupCooperative group settingHigh-grade NHLNational Cancer InstituteSame time pointsVs 53Aggressive NHLII studyOncology Group
1988
The role of chemotherapy in diffuse aggressive lymphomas.
DeVita V, Hubbard S, Young R, Longo D. The role of chemotherapy in diffuse aggressive lymphomas. Seminars In Hematology 1988, 25: 2-10. PMID: 3041598.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsDrug EvaluationHumansLymphoma, Non-HodgkinPrognosisConceptsDiffuse aggressive lymphomasEarly-stage diseaseCombination chemotherapyAggressive lymphomaDose intensityNew combination chemotherapy programScheduling of drugsDurable complete remissionRole of chemotherapyCombination chemotherapy programsImportant prognostic factorEnd of treatmentComplete remissionStage diseaseChemotherapy programPrognostic factorsSubsequent radiotherapyRisk factorsPrimary treatmentAdditional drugsChemotherapyOld drugsAdvanced stageLymphomaRadiotherapy
1981
Animal toxicology for early clinical trials with anticancer agents.
Rozencweig M, Von Hoff D, Staquet M, Schein P, Penta J, Goldin A, Muggia F, Freireich E, DeVita V. Animal toxicology for early clinical trials with anticancer agents. American Journal Of Clinical Oncology 1981, 4: 21-8. PMID: 6783332.Peer-Reviewed Original ResearchConceptsPhase I clinical trialEarly clinical trialsClinical trialsOrgan system toxicityStarting doseSystem toxicityChemotherapeutic agentsDose-escalation stepsCommon toxic effectsGastrointestinal intoleranceInitial doseClinical dataEscalation stepsAnimal findingsToxic doseToxic manifestationsIndividual drugsPredictive valueAnimal toxicologyMiceDoseIdentical scheduleLD10Acceptable dosesDogs
1980
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.
Speyer J, Collins J, Dedrick R, Brennan M, Buckpitt A, Londer H, DeVita V, Myers C. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Research 1980, 40: 567-72. PMID: 7471076.Peer-Reviewed Original ResearchConceptsPeritoneal fluid concentrationsPlasma levelsGram-negative bacterial peritonitisTenckhoff peritoneal dialysis catheterCentral nervous system toxicityStudy of 5-fluorouracilDose-limiting toxicityPeritoneal fluid levelsSimultaneously measured plasma levelsPhase I studyPeritoneal dialysis catheterNervous system toxicityMild abdominal discomfortRoute of administrationTotal body clearanceFluid concentrationsPattern of toxicityBacterial peritonitisDialysis catheterAbdominal discomfortSystemic toxicityPharmacological advantagesDialysate concentrationsBody clearanceFluid levelsGeneral Progress in Clinical Chemotherapy of Advanced Disease
Muggia F, Henney J, DeVita V. General Progress in Clinical Chemotherapy of Advanced Disease. Recent Results In Cancer Research 1980, 74: 1-7. PMID: 7003657, DOI: 10.1007/978-3-642-81488-4_1.Peer-Reviewed Original ResearchConceptsAggressive systemic treatmentMinimal residual diseaseTumor cell cytotoxicityAdvanced diseaseImmunologic factorsSystemic treatmentLocal therapyAdvanced cancerTumor burdenResidual diseaseTumor controlCurative approachLocoregional drug deliveryClinical chemotherapySuccessful chemotherapyEffective drugsDrug pharmacologyCell cytotoxicityInfectious diseasesDiseaseChemotherapyCancerCurrent resultsCellular heterogeneityTherapy
1978
New Anticancer Drugs
Muggia F, Bono V, DeVita V. New Anticancer Drugs. Antibiotics And Chemotherapy 1978, 23: 42-49. PMID: 646328, DOI: 10.1159/000401470.Peer-Reviewed Original Research
1976
Perspectives on research in gynecologic oncology. Treatment protocols
Devita V, Wasserman T, Young R, Carter S. Perspectives on research in gynecologic oncology. Treatment protocols. Cancer 1976, 38: 509-525. PMID: 776390, DOI: 10.1002/1097-0142(197607)38:1<509::aid-cncr2820380175>3.0.co;2-a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAlkylating AgentsAntineoplastic AgentsCarcinoma, Squamous CellClinical Trials as TopicDrug EvaluationDrug Therapy, CombinationFemaleGenital Neoplasms, FemaleHumansHysterectomyMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsProgestinsUterine Cervical NeoplasmsUterine NeoplasmsConceptsClinical trialsOvarian cancerAdvanced uterine cancerPostoperative adjuvant chemotherapyStage II diseaseMetastatic cervical cancerEffective adjuvant treatmentEffect of radiotherapyUse of adriamycinUse of hydroxyureaCombination of drugsL-phenylalanine mustardPathways of spreadMore effective drugsAdjuvant chemotherapyInoperable diseaseResectable tumorsAdjuvant treatmentAdvanced diseasePostoperative radiotherapySystemic chemotherapyGynecologic malignanciesSystemic treatmentTreatment failureUterine cervixChemotherapy research nurse.
Hubbard S, Devita V. Chemotherapy research nurse. American Journal Of Nursing 1976, 76: 560-5. PMID: 818899, DOI: 10.2307/3423770.Peer-Reviewed Original Research
1975
Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan.
Canellos G, Young R, Neiman P, DeVita V. Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan. Blood 1975, 45: 197-203. PMID: 1054609, DOI: 10.1182/blood.v45.2.197.bloodjournal452197.Peer-Reviewed Original ResearchConceptsTreatment of chronic granulocytic leukemiaBusulfan-treated patientsChronic granulocytic leukemiaGranulocytic leukemiaMedian duration of disease controlChronic phase of CGLDuration of disease controlContinuous maintenance therapyElevated leukocyte countTreated with busulfanIncreased skin pigmentationMyelosuppressive actionRemission inductionMaintenance therapyMedian survivalMedian durationBlastic transformationPulmonary fibrosisBusulfanRandomized comparisonChronic phaseLeukocyte countDibromomannitolPatientsCytological dysplasia
1974
Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998)
Schein P, O'Connell M, Blom J, Hubbard S, Magrath I, Bergevin P, Wiernik P, Ziegler J, Devita V. Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998). Cancer 1974, 34: 993-1000. PMID: 4371075, DOI: 10.1002/1097-0142(197410)34:4<993::aid-cncr2820340404>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsMalignant carcinoid tumorsNormal renal functionIslet cell carcinomaClinical antitumor activityAcute lymphocytic leukemiaToxicity of streptozotocinHematologic toxicityAdvanced malignanciesRenal damageRenal functionCarcinoid tumorsHodgkin's diseaseCell carcinomaLymphocytic lymphomaTherapeutic responseLymphocytic leukemiaTumor massBurkitt's lymphomaDrug effectsMaximum dosesPatientsTotal doseStreptozotocinLymphomaAntitumor activity
1973
Current chemotherapeutic combinations.
DeVita V, Carbone P. Current chemotherapeutic combinations. Series Haematologica (1968) 1973, 6: 182-95. PMID: 4593779.Peer-Reviewed Original Research